Figure 2

Vidofludimus anti‑PRRSV activity in Marc‑145 cells. A Viability of Marc-145 cells treated with the indicated concentrations of Vi for 48 h. B Western blot of N-protein in cells infected with PRRSV and treated with the indicated concentrations of Vi. C Relative PRRSV ORF7 mRNA levels determined by qRT-PCR. GAPDH was used as reference control. D Virus titration by TCID₅₀ calculation. E Light microscopy and IFA detection of Marc-145 cells (PRRSV-infected and Vi-treated), at 48 hpi. Green, PRRSV N-protein; blue, nucleus. Scale bars, 500 μm. F and G Western blot of N-protein and TCID₅₀ detection in cells infected with different PRRSV genotypes Vi or DMSO treatment. H EC₅₀ of Vi on PRRSV NADC30-like strain FJ1402. I EC₅₀ of Vi on PRRSV classical strain S1. Error bars represent the mean ± SD. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, not significant.